Biomarkers and HIV-associated cardiovascular disease

被引:53
|
作者
Baker, Jason V. [1 ,2 ]
Duprez, Daniel [3 ]
机构
[1] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
[2] Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA
[3] Univ Minnesota, Div Cardiovasc, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院;
关键词
biomarkers; cardiovascular disease; coagulation; endothelial dysfunction; HIV infection; inflammation; lipoproteins; thrombosis; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; INTERCELLULAR-ADHESION MOLECULE-1; INTIMA-MEDIA THICKNESS; ENDOTHELIAL ACTIVATION MARKERS; FUTURE MYOCARDIAL-INFARCTION; ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; INFECTED PATIENTS; S DEFICIENCY;
D O I
10.1097/COH.0b013e32833ed7ec
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review Our goal is to summarize recent literature on biomarkers of cardiovascular disease (CVD) in the setting of HIV infection with an emphasis on those associated with clinical events. Recent findings Epidemiological data have demonstrated that HIV infection is associated with increases in well established markers of inflammation and thrombosis, and levels of high sensitivity C-reactive protein, interleukin-6, and D-dimer predict CVD and mortality risk in HIV cohorts. Levels of interleukin-6, D-dimer and endothelial adhesion molecules increase when antiretroviral therapy is interrupted, suggesting that HIV replication may be driving CVD risk in this context. However, data on changes in many CVD biomarkers after starting antiretroviral therapy are inconsistent or lacking. Finally, high-density lipoprotein particles may be more informative than other lipoprotein measures for CVD risk specifically among individuals with HIV infection. Summary Biomarkers of inflammation and thrombosis have the potential to improve CVD risk stratification beyond traditional and HIV-specific factors, and may prove useful for evaluating CVD prevention strategies for individuals with HIV infection.
引用
收藏
页码:511 / 516
页数:6
相关论文
共 50 条
  • [1] Pathogenesis of HIV-associated cardiovascular disease
    Barbaro, G
    HIV INFECTION AND THE CARDIOVASCULAR SYSTEM, 2003, 40 : 49 - 70
  • [2] Plasma Biomarkers of HIV-associated Cognitive Disease
    Winston, Alan
    Underwood, Jonathan
    EBIOMEDICINE, 2016, 3 : 12 - 13
  • [3] HIV-associated cardiovascular disease is global scourge
    Harper, Kirsten Nicole
    AIDS, 2019, 33 (03) : N2 - N3
  • [4] HIV-Associated Cardiovascular Disease: Beyond the Macrovascular
    Pournamdari, Ashley B.
    Hsue, Priscilla Y.
    Parikh, Rushi V.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (22):
  • [5] Pathological findings of HIV-associated cardiovascular disease
    D'Amati, G
    Di Gioia, CRT
    Gallo, P
    HIV-ASSOCIATED CARDIOVASCULAR DISEASE: CLINICAL AND BIOLOGICAL INSIGHTS, 2001, 946 : 23 - 45
  • [6] CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease
    Clifford, D. B.
    Fagan, A. M.
    Holtzman, D. M.
    Morris, J. C.
    Teshome, M.
    Shah, A. R.
    Kauwe, J. S. K.
    NEUROLOGY, 2009, 73 (23) : 1982 - 1987
  • [7] HIV-Associated Cardiovascular Disease Role of Connexin 43
    Prevedel, Lisa
    Morocho, Camilla
    Bennett, Michael V. L.
    Eugenin, Eliseo A.
    AMERICAN JOURNAL OF PATHOLOGY, 2017, 187 (09): : 1960 - 1970
  • [8] HIV-Associated Cardiovascular Disease: Role of Connexin43
    Prevedel, Lisa
    Morocho, Camilla
    Bennett, Michael V.
    Morgello, Susan
    Eugenin, Eliseo A.
    JOURNAL OF GENERAL PHYSIOLOGY, 2016, 148 (02): : 31A - 32A
  • [9] Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes
    Fisher, SD
    Bowles, NE
    Towbin, JA
    Lipshultz, SE
    AIDS, 2003, 17 : S29 - S35
  • [10] HIV-associated lung disease
    Nature Reviews Disease Primers, 9